-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
AffaMed Therapeutics (hereinafter referred to as "AffaMed"), a clinical-stage innovative pharmaceutical company dedicated to meeting the global needs for the treatment of ophthalmic, neurological and psychiatric diseases, today announced the establishment of a wholly-owned subsidiary, AffaMed Digital
.
The new company will focus on the development and commercialization of evidence-based and clinically proven digital therapies
Dr.
Dayao Zhao, CEO of AffaMed, said: "The establishment of AffaMed Digital marks another critical step forward in our business development
.
This subsidiary will focus on innovation in the field of digital therapy, and promote our digital treatment, intervention and diagnosis systems.
"Focusing on the fields of ophthalmology, neurological and psychiatric diseases, the establishment of AffaMed Digital is an important step in our strategy to integrate digital solutions and expand our existing product portfolio.
It once again highlights our commitment to becoming a global innovation leader.
In September 2021, AffaMed announced the establishment of a strategic partnership with Beijing Tiantan Hospital affiliated to Capital Medical University and Beijing Wujiang Brain Technology Co.
, Ltd.
(hereinafter referred to as "IBT") to jointly develop digital therapies for neurological diseases
.
On this basis, AffaMed has further reached a licensing agreement with IBT to obtain global rights to develop and commercialize new digital therapies for the treatment of post-stroke cognitive impairment (hereinafter referred to as "PSCI") and other indications
In the context of the rapid development of global science and technology, more and more clinical studies have shown that digital therapy is indeed effective in the treatment of certain diseases
.
Peer-reviewed studies have shown that in the treatment of many indications including ADHD, asthma, schizophrenia and insomnia1, whether applied alone or in combination with traditional treatment options, digital therapies have achieved better treatments Effect
1.
2.
